

Contents

Foreword	xv
Preface	xix
Summary points and recommendations	xix
Background	xxii
Background to the second edition	xxii
Background to the first edition	xxvi
The changing regulatory environment	xxvii
Introduction	xxx
More education rather than more regulation	xxx
The need to identify investment risk	xxxix
Target readership	xxxiii
Commercial benefits to compliance	xxxiii
Local differences and specific circumstances	xxxiv
Summary	xxxiv
Case studies and examples	xxxv
Themes	xxxvii
Research coverage	xxxvii
Sourcing information	xxxviii
Reasonable basis for recommendations and risk assessment	xxxix
Conflicts of interest	xl
Writing in general	xli
Acknowledgments	xlvi
Abbreviations Used in This Book	xlvii
Chapter 1: Principles of Research	1
Key points	2
Definition and supervision of research	2
Supervision and control of research	2
Marketing research to the U.S. by foreign broker-dealers	3
Stock-picking tips	8
Continuing education	9
Cheating in tests	10
The realm of research	11
Ambit of securities regulations (bonds)	12
Ambit of securities research regulations (equity and credit research analysts)	13
Ambit of securities regulations (swaps and other derivatives)	16

Ambit of securities research regulations (marketers of research, including hedge fund research)	19
Ambit of securities research regulations (analysts as experts on sales desks)	20
Ambit of securities research regulations (stock-tipping bloggers)	21
Ambit of securities research regulations (media commentators)	23
Minimizing approval and publishing risks	26
Honesty and fair treatment of clients	28
Common securities-related violations cited by the SEC and FINRA of the U.S.	28
Regulations tightening up around the world (Hong Kong)	29
Regulations tightening up around the world (China)	31
Regulations tightening up around the world (Japan)	32
Front-running and selective distribution of research	35
Front-running and selective distribution of research (huddles)	35
Front-running of research	36
Selective distribution of research	37
Selective distribution of research (fact-checking)	39
Selective distribution of research (greater conviction of view)	39
Insider dealing and selective disclosure	41
Use/dissemination of price-sensitive information (general)	44
Use/dissemination of price-sensitive information (U.S.)	47
Use/dissemination of price-sensitive information (U.K.)	48
Use/dissemination of price-sensitive information (Hong Kong)	50
Use/dissemination of price-sensitive information (serial insider trading)	53
Use/dissemination of price-sensitive information (pillow talk)	54
Use/dissemination of price-sensitive information (economists)	56
Specific requests and proprietary information	58
Definition of publishing	59
Unfair portrayal of past recommendations	60
Performance of past recommendations	60
Conflicts of interest and disclosure of interests	62
Catering to investors with specific investment criteria	62
<i>Shari'ah</i> law implications for securities research analysts (stocks)	64
<i>Shari'ah</i> law implications for securities research analysts (bonds)	65
The virtues of a vice portfolio	67
Analyst surveys	67
Playing the voting "game"	68
Sourcing information	71
Acknowledging the source	71
Gathering confidential information	72
Receiving confidential information	76

Rumors, speculation and M&A	79
Identifying M&A candidates (putting companies into play)	81
Short selling by hedge funds (abusive rumor-mongering)	84
Defamation—libel and slander	88
Defamation	89
Intellectual property—copyright and plagiarism	91
Intellectual property	91
Research integrity and consistency	95
The problem	95
Disgruntled clients	95
The principles	96
. . . be consistent or explain apparent inconsistencies	97
Sector/country weightings and universes	100
Consistency of views	101
Top picks (research requirements)	102
Consistency of views	104
Technical analysis	105
Useful qualifications (technical analysis)	106
Coverage universe—initiations, terminations and transfers	106
Accountability principles	106
Initiation of coverage	107
Transfer or re-initiation of coverage	107
Co-authorship liability	108
Termination of coverage	109
“Under review”	110
Publishing new research	111
No recommendation?	111
No recommendations	114
Chapter 2: Reasonable Basis, Valuations and Risk	119
Key points	120
Consistency of recommendations	121
Explanation for inconsistencies	121
Following the market	122
Valuation support	122
Forensic analysis of accounts	122
Channel-stuffing and other activities	123
Cross-industry antitrust issues	124
Disclosures and notes	126
<i>Pro-forma</i> accounting and use of selective data	128
Reasonableness of valuations	128
Highlight valuation changes	129
The appropriate valuation methodology	129
Unrealistic expectations or questionable bases for valuation	130
Excessive valuations	132
Highlighting risks and volatility	133
Appropriateness of sell ratings	134
Short-selling by hedge funds (pushing the envelope?)	135

Management's reaction to negative research (legal action)	137
Management's reaction to negative research (restricting information)	138
Mis-selling and not highlighting risks	139
Highlighting investment risks (credit crisis of 2007/08, U.S.)	139
Highlighting investment risks (credit crisis of 2007/08, global)	142
Highlighting investment risks (general)	144
Evaluating risks and catalysts	146
Catalysts and consensus	147
Market liquidity and contagion risks	147
Foreign exchange and interest rate risks	147
Currency risks	148
Earnings risks	150
Brand theft risk	151
Brand theft	151
Brand usurping	152
Cashflow and liquidity risks	153
Valuation risks	153
Modeling and miscalculation risks	154
Modeling risks	155
Mispricing risks	156
Information risk	157
M&A risks	158
Corporate governance risks	159
Gauging corporate governance risks	159
Social responsibility	161
Corporate governance (social responsibility—rankings)	161
Durability of brand names	163
Corporate governance (social responsibility—the mass-consumer market)	164
Corporate governance (social responsibility—corporate governance excellence)	165
Executive remuneration	167
Corporate governance (executive remuneration)	168
Corporate governance (executive remuneration—disclosures)	172
Executive insider trading	174
Corporate governance (executive insider trading)	175
Equal treatment of shareholders	176
Corporate governance (equal treatment of shareholders)	177
Corporate governance (related-party transactions)	179
Corporate governance (equal treatment of shareholders—related-party transactions)	181
Corporate governance (vote manipulation)	182
Corporate governance (independent non-executive directors)	184
National interest	184
Corporate governance (national interest)	184
Corporate governance (national interest—strategic industries)	187

Corporate governance (national interest—sovereign wealth funds)	189
Risk management	189
Corporate governance (false statements by issuers)	190
Corporate governance (risk management and rogue traders)	191
Corporate governance (transparency of operations)	196
Ponzi schemes	197
Corporate governance (risk management and money-laundering, bribery and corruption)	199
Credit rating risks	201
Analyzing risk (credit rating agencies)	201
Due diligence by investment bankers	203
Due diligence (failures)	204
Chapter 3: Independence of Research and Conflicts of Interest	209
Key points	210
Summary	210
Separating research and banking	211
Conflicts of interest (global settlements)	212
Conflicts of interest (collateralized debt obligations)	214
Conflicts of interest (auction-rate securities)	216
Managing contacts between analysts and bankers	217
Disclosures of interests and relationships	219
Conflicts of interest (private trading contrary to recommendations)	220
Analyst certification	221
Conflicts of interest (disclosures)	222
Writing research on banking clients	223
Conflicts of interest (watch lists)	225
Conflicts of interest (managing apparent conflicts)	226
“Pre-deal” research	230
Conflicts of interest (pre-deal research)	231
Influencing of analysts by issuers	234
Conflicts of interest (bribes)	234
Conflicts of interest (favors)	235
Conflicts of interest (issuers guiding analysts)	236
Conflicts of interest (employment)	237
Independent research firms	238
Alleged conflicts of interest (independent research firms)	239
Paying for sell-side research	242
Transparency in paying for research (inappropriate payments)	245
Paying for credit ratings	246
Chapter 4: Non-research: E-mails, Blogs and Internal Communications	251
Key points	252
Approval of e-mail and media appearances	253

Objective commentary on non-rated companies	254
E-mails	256
E-mails as research	257
Retention of e-mails	259
“Internal Use Only”	261
Chapter 5: General Writing, Editing and Publishing Considerations	263
Key points	264
Introduction	264
Getting the message across	265
Headlines and covers	265
Standards of taste	266
Bullets, key points and executive summaries	267
Publishing and distribution	267
Writing the text	268
Writing rules	268
Use the right word	269
Vocabulary for attributing forward-looking comments (using “will”)	269
Measurements and direction/degree of movement	271
Vocabulary for describing movement and performance	272
Words to avoid or use carefully	273
Bullshit Bingo (vocabulary and phrases)	274
Clarity of communication	275
Clarity, consistency, conformity and continuity	276
Be consistent or explain inconsistencies	277
Editorial departments and style guides	277
Translations into different languages	278
Mistranslations	278
Publishing independent yet integrated reports	279
Sensitivity to politics and religion	280
Sensitivity to politics and religion	280
Correcting errors	281
Courses of corrective action	281
Materiality of the error	282
Publishing of out-of-date story	282
Retractions	283
Helping the reader	286
Index	287